In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide IGF-1 (mecasermin) | Natural peptide HGH (somatotropin) | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Natural peptide | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 415 (plus 6 on natural levels, listed separately) | 1,108 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 55 (55 in people) | 110 (108 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 52 · 3 active254 more mention it but do not test it | 358 · 32 active72 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Increlex says: “Growth failure in children aged 2 years and older with severe primary IGF-1 deficiency, or GH gene deletion with neutralizing antibodies to GH”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | IGF-1 (mecasermin) | HGH (somatotropin) |
|---|---|---|
| Bone and jointMusculoskeletal | 52502 | 12611511 |
| Glycemic control |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Genotropin says: “Replacement in adults with adult-onset or childhood-onset GHD”
7474 |
8585 |
| Growth hormone and IGF-1Metabolic and weight | 655483 | 1069115 |
|---|
| Linear growthEndocrine and hormones | 11 | 1301264 |
|---|
| Body compositionMetabolic and weight | 1313 | 109109 |
|---|
| Adverse eventsWhole body | 4646 | 60582 |
|---|
| LipidsMetabolic and weight | 1111 | 7373 |
|---|
| Body weightMetabolic and weight | 1082 | 46415 |
|---|
| Protein and amino acid metabolismMetabolic and weight | 1818 | 3131 |
|---|
| Exercise and physical functionNervous system and cognition | 66 | 4141 |
|---|
| PharmacokineticsPharmacology | 3131 | 23320 |
|---|
| Kidney functionKidney and urinary | 2020 | 1212 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | IGF-1 (mecasermin) | HGH (somatotropin) |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in cm/year | No comparable result 6 randomized-trial results measure it in another way or another unit. | 9.78 cm/year Height velocity · somatropin at month 12 Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2282022 |
| Bone and jointMusculoskeletalCompared as: difference from placebo, in p value | 0.05 P value P value for spinal bone density change comparison Dose studied: 30 microg/kg twice daily9 monthsn = 602002 | No comparable result 29 randomized-trial results measure it in another way or another unit. |
| Kidney functionKidney and urinaryCompared as: difference from placebo, in p value | 0.67 p value P value for day 7 inulin clearance comparison Dose studied: 100 mg/kg twice a day6 daysn = 432003 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in unitless | −0.03 unitless P value for HbA1c reduction versus placebo · Shown as a change. The study reports a p value for hba1c reduction versus placebo of this size. Dose studied: 40 microg/kg daily24 weeksn not reported1997 | |
| Linear growthEndocrine and hormonesCompared as: value in the arm that got the peptide, in cm/yr | 2.9 cm/yr Growth rate · rhIGF-I recipients, before therapy (2.9 +/- 0.6) Dose studied: 120 micrograms/kg daily12 monthsn not reported1995 | No comparable result 42 randomized-trial results measure it in another way or another unit. |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 17 randomized-trial results measure it in another way or another unit. | 79.1% Treatment-emergent adverse events Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2242022 |
No comparable result
6 randomized-trial results measure it in another way or another unit.
9.78 cm/year
Height velocity · somatropin at month 12
Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2282022
No comparable result 8 randomized-trial results measure it in another way or another unit. |
0.05 P value
P value for spinal bone density change comparison
Dose studied: 30 microg/kg twice daily9 monthsn = 602002
No comparable result
29 randomized-trial results measure it in another way or another unit.
0.67 p value
P value for day 7 inulin clearance comparison
Dose studied: 100 mg/kg twice a day6 daysn = 432003
No comparable result
2 randomized-trial results measure it in another way or another unit.
−0.03 unitless
P value for HbA1c reduction versus placebo · Shown as a change. The study reports a p value for hba1c reduction versus placebo of this size.
Dose studied: 40 microg/kg daily24 weeksn not reported1997
No comparable result
8 randomized-trial results measure it in another way or another unit.
2.9 cm/yr
Growth rate · rhIGF-I recipients, before therapy (2.9 +/- 0.6)
Dose studied: 120 micrograms/kg daily12 monthsn not reported1995
No comparable result
42 randomized-trial results measure it in another way or another unit.
No comparable result
17 randomized-trial results measure it in another way or another unit.
79.1%
Treatment-emergent adverse events
Dose studied: 0.24 mg/kg/week once daily12 monthsn = 2242022
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 52 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
The University of Texas Medical Branch, Galveston644 participantsJul 2000 to Apr 2013
Burns
Mayo Clinic330 participantsJun 2003 to Dec 2007
Amyotrophic Lateral Sclerosis
Ipsen137 participantsMar 2004 to Jul 2008
Growth Disorders · Insulin-Like Growth Factor-1 Deficiency
254 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 358 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S712 participantsJul 2007 to Dec 2008
Chronic Kidney Disease · End-Stage Renal Disease
EMD Serono326 participants28 May 2004 to 28 Sept 2005
HIV Infections · Lipodystrophy
Pfizer316 participantsDec 2006 to Aug 2012
Idiopathic Short Stature
72 more mention it but do not test it. They only measure it or name it in their text.